Suchergebnisse - "Gaylis, Norman B"

PubPharm (31)

1

Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC)-The hunt for effective treatments

enthalten in: The Journal of infection | 2024

von Gaylis, N. | Yang, O.

2

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Recknor, C. | Hansen, S. | Gaylis, N. | +3

CommentOn: Clin Infect Dis. 2022 Oct 12;75(8):1485-1486. - PMID 35819236

3

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Gaylis, N. | Ritter, A. | Kelly, S. | +6

CommentIn: Clin Infect Dis. 2022 Oct 12;75(8):1485-1486. - PMID 35819236

4

The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID

enthalten in: Frontiers in nutrition | 2022

von Gaylis, N. | Kreychman, I. | Sagliani, J. | +2

5

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis : 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2020

von Wiland, P. | Jeka, S. | Dokoupilová, E. | +9

6

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

enthalten in: BioDrugs | 2020

von Wiland, P. | Jeka, S. | Dokoupilová, E. | +9

7

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

enthalten in: BioDrugs | 2020

von Wiland, P. | Jeka, S. | Dokoupilová, E. | +9

8

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

enthalten in: BioDrugs | 2020

von Wiland, P. | Jeka, S. | Dokoupilová, E. | +9

9

Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis : a two-stage multicentre, randomised pilot study

enthalten in: The Lancet. Rheumatology | 2020

von Genovese, M. | Gaylis, N. | Sikes, D. | +6

10

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

enthalten in: Patient preference and adherence | 2017

von Gaylis, N. | Sagliani, J. | Black, S. | +4